The Einstein Center for Epigenomics Signs Site License Agreement with CLC bio
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
The Einstein Center for Epigenomics at the Albert Einstein College of Medicine in Bronx, New York, has entered into an agreement with CLC bio to put the company's full suite of bioinformatics tools into the hands of epigenomics researchers and other investigators at the College.
The suite includes CLC bio’s solutions for handling high-throughput sequencing data, CLC Genomics Workbench and CLC Genomics Server.
Dr. John Greally, director of the Einstein Center for Epigenomics, is enthusiastic about the multi-year partnership, noting, "CLC bio's tools are going to put sophisticated analytical ability into the hands of molecular biologists at Einstein, and will greatly enhance their ability to explore the massively-parallel sequencing data that we are generating. We see this as a way of lowering barriers for scientists who have not previously performed these high-throughput epigenomic assays, allowing them to explore their data and explore hypotheses."
CEO at CLC bio USA, Jan Lomholdt, comments, "We’re very happy to announce this site license agreement and look forward to working with and getting valuable feedback from world-renowned scientists at Einstein. This agreement is yet another stamp of approval by the scientific community in North America, where CLC bio is currently getting a strong foothold. We will be announcing more exciting agreements in the near future."
The suite includes CLC bio’s solutions for handling high-throughput sequencing data, CLC Genomics Workbench and CLC Genomics Server.
Dr. John Greally, director of the Einstein Center for Epigenomics, is enthusiastic about the multi-year partnership, noting, "CLC bio's tools are going to put sophisticated analytical ability into the hands of molecular biologists at Einstein, and will greatly enhance their ability to explore the massively-parallel sequencing data that we are generating. We see this as a way of lowering barriers for scientists who have not previously performed these high-throughput epigenomic assays, allowing them to explore their data and explore hypotheses."
CEO at CLC bio USA, Jan Lomholdt, comments, "We’re very happy to announce this site license agreement and look forward to working with and getting valuable feedback from world-renowned scientists at Einstein. This agreement is yet another stamp of approval by the scientific community in North America, where CLC bio is currently getting a strong foothold. We will be announcing more exciting agreements in the near future."
